Pfizer Inc. Q3 Earnings: The Most Important Things to Know
Pfizer's (NYSE: PFE) overall story so far in 2017 has been a mediocre one. The big pharma company's stock is up year to date, but barely half as much as the S&P 500 index. Although Pfizer topped earnings estimates in the first two quarters of 2017, its top-line growth was either weak or nonexistent. But even in the midst of general mediocrity, there has been some good news.
Investors were hoping for more good news when Pfizer announced its third-quarter earnings results before the market opened on Tuesday. And they got some. However, they also received some bad news, along with some so-so news as well. Here's what you need to know the most from Pfizer's third-quarter earnings results.
Image source: Getty Images.
Source: Fool.com
Pfizer Inc. Aktie
25,77 €
0,14 %
Die Pfizer Inc. Aktie steht gut da: Deutlich mehr Buy- als Sell-Einschätzungen in der Community.
Das Kursziel von 41 € für Pfizer Inc. impliziert eine deutliche Steigerung um über 50% gegenüber 25.77 €.
